Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1Phase 1 1

Status

Unknown 4Recruiting 4Terminated 3Active not recruiting 3Not yet recruiting 2Completed 2Available 1Approved for marketing 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 46Plasma cell 29Other hematologic neoplasm 25CNS 12Genitourinary 10Gastrointestinal 10Dermatologic 9Breast 8Head & Neck 7Gynecologic 7Myeloid 6Sarcoma 5Thoracic 4Endocrine 3Other neoplasm 1NET 1Classical hematology 1

Conditions

Neuroendocrine Tumors 51Thyroid Neoplasms 19Thyroid Cancer, Papillary 16Carcinoma, Neuroendocrine 16Pheochromocytoma 11Adrenocortical Carcinoma 11Thyroid Carcinoma, Anaplastic 10Gastro-enteropancreatic neuroendocrine tumor 10Small Cell Lung Carcinoma 9Pituitary Neoplasms 9Paraganglioma 9Multiple Endocrine Neoplasia Type 1 9Lung Neoplasms 8Adenoma, Islet Cell 8Sarcoma 6Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Carcinoma, Medullary 6Adenocarcinoma, Follicular 6Central Nervous System Neoplasms 5Carcinoma, Renal Cell 5Carcinoid Tumor 5Somatostatinoma 4Neuroblastoma 4Neoplasm Metastasis 4Colorectal Neoplasms 4Cholangiocarcinoma 4Carcinoma, Merkel Cell 4Carcinoma, Hepatocellular 4Brain Neoplasms 4

Interventions

entrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Recurrence × Endocrine × Clear all
NCT02650401 2026-03-25

STARTRK-NG

Hoffmann-La Roche

Phase 1/2 Active not recruiting
69 enrolled 1 FDA
CNSEndocrineGenitourinaryHead & NeckSarcoma

Thyroid Cancer, Papillary, Brain Neoplasms, Glioma, Medulloblastoma, Neoplasm Metastasis, Wilms Tumor, Neuroblastoma, Recurrence, Salivary Gland Neoplasms, Sarcoma, Sarcoma, Ewing, Central Nervous System Neoplasms, Nephroma, Mesoblastic

NCT06148636 2025-11-04

A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors

University of Iowa

Phase EARLY_PHASE1 Active not recruiting
24 enrolled
EndocrineNET

Adenoma, Islet Cell, Recurrence, Neuroendocrine Tumors

NCT04420754 2025-03-30

Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer

AffyImmune Therapeutics, Inc.

Phase 1 Active not recruiting
70 enrolled
EndocrineHead & Neck

Recurrence, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡